左西孟旦与米力农治疗顽固性心力衰竭疗效和安全性的对比研究
发布时间:2018-11-25 16:46
【摘要】:目的:对比分析左西孟旦注射液与米力农注射液治疗顽固性心力衰竭临床疗效,并对二者安全性及预后进行评价。方法:选取2014年9月至2015年9月于山东省单县中心医院住院的顽固性心力衰竭的住院患者80例,随机分为左西孟旦组和米力农组,每组40例。两组均给予常规抗心力衰竭治疗,包括吸氧、去除诱因、应用利尿类、血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂(ACEI类或ARB)、β-受体阻滞剂、醛固酮受体拮抗剂、洋地黄类、血管活性药物、硝酸酯类等常规药物治疗。随后试验组给予左西孟旦注射液(悦文,山东齐鲁制药有限公司),先以12μg/Kg的负荷量静脉注射(时间≥10分钟),再以0.1ug/(kg.min)静脉泵入,1小时后酌情减半或加倍持续静脉泵入,共维持24小时。对照组给予米力农注射液(鲁南力康,鲁南贝特制药有限公司),先以50ug/kg的负荷量静脉注射(时间≥10分钟),之后酌情按照0.375-0.75ug/(kg.min)持续静脉泵入,共维持24小时。用药7天后,对比两组呼吸困难改善症状及心功能分级有无好转;对比两组氨基末端脑钠肽前体(NT-pro BNP)水平、左心室射血分数(LVEF)值、每搏输出量(SV);记录用药期间不良反应;统计平均住院天数,随访出院三个月内再住院率及死亡率。结果:治疗前两组年龄、性别、高危因素、基础疾病等一般基线资料的比较,数据差异均无统计学意义(P0.05)。治疗7天后:米力农组的心功能改善及呼吸困难等症状缓解总有效率达72.5%,而左西孟旦组为92.5%,且左西孟旦组达到显效的是米力农组的1.7倍,两组数据对比有统计学意义(P0.05);治疗前两组病人LVEF、SV及NT-pro BNP数据对比无统计学差异(P0.05),治疗后两组LVEF及SV均明显上升,左西孟旦组升高差值优于米力农组,两组数据比较差异具有统计学意义(P0.05);NT-pro BNP方面,左西孟旦组较米力农组降低差值更加显著,数据差异有统计学意义(P0.05)。左西孟旦组总的不良反应发生率12.5%,低于米力农组的22.5%,数据差异有统计学意义(P0.05)。左西孟旦组平均住院天数13.5±4.5天,较米力农组16.5±6.5天短;预后方面,左西孟旦组三个月再入院率及死亡率较米力农组低,数据差异均有统计学意义(P0.05)。结论:1左西孟旦注射液治疗顽固性心力衰竭临床疗优于米力农注射液,能够更加显著的缓解临床症状及改善心功能分级。2左西孟旦与米力农相比较,在提升顽固性心力衰竭的左室射血分数(LVEF)、每搏心输出量(SV)方面、降低氨基末端脑钠肽前体(NT-Pro BNP)更有优势。3左西孟旦注射液安全性良好,平均住院天数相对较少,且有减少3个月死亡率、再住院率的趋势。
[Abstract]:Objective: to evaluate the safety and prognosis of levosimendan injection and milrinone injection in the treatment of refractory heart failure. Methods: from September 2014 to September 2015, 80 patients with refractory heart failure in Shanxian Central Hospital of Shandong Province were randomly divided into two groups: levosimendan group and milrinone group with 40 cases in each group. Both groups were given routine anti-heart failure therapy, including oxygen inhalation, removal of inducement, diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor antagonists (ACEI or ARB), 尾 -blockers, aldosterone receptor antagonists). Digitalis, vasoactive drugs, nitrates and other routine drug treatment. Then the experimental group was treated with levosimendan injection (Yuewen, Shandong Qilu Pharmaceutical Co., Ltd.), which was injected intravenously with a load of 12 渭 g/Kg (time 鈮,
本文编号:2356794
[Abstract]:Objective: to evaluate the safety and prognosis of levosimendan injection and milrinone injection in the treatment of refractory heart failure. Methods: from September 2014 to September 2015, 80 patients with refractory heart failure in Shanxian Central Hospital of Shandong Province were randomly divided into two groups: levosimendan group and milrinone group with 40 cases in each group. Both groups were given routine anti-heart failure therapy, including oxygen inhalation, removal of inducement, diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor antagonists (ACEI or ARB), 尾 -blockers, aldosterone receptor antagonists). Digitalis, vasoactive drugs, nitrates and other routine drug treatment. Then the experimental group was treated with levosimendan injection (Yuewen, Shandong Qilu Pharmaceutical Co., Ltd.), which was injected intravenously with a load of 12 渭 g/Kg (time 鈮,
本文编号:2356794
本文链接:https://www.wllwen.com/yixuelunwen/xxg/2356794.html
最近更新
教材专著